You signed your first design partner three weeks ago. The logo is already on your homepage.
It feels like proof. It isn't, not yet. And the clinicians and investors you're trying to win over can tell the difference faster than you'd like.
What a logo actually promises
A logo on a website makes one implicit claim: this organization trusted us enough to work with us, and something good came of it.
Three weeks into a pilot, you can honestly claim the first half. You can't claim the second. Nobody's outcome has happened yet. You don't have a baseline, you don't have a result, and you almost certainly don't have permission to say anything specific about either.
So the logo is doing work it hasn't earned. It's borrowing the credibility of a finished case study for a relationship that's still in progress. Most buyers won't call that out to your face. They'll just discount it quietly and keep scrolling.
Why clinical buyers read logos this way
A physical therapy group that's been burned by three "in partnership with" claims that turned out to mean an unsigned intro call learns to discount every logo wall it sees. So does a clinic director who's clicked through a "trusted by leading providers" banner and found a single pilot from eighteen months ago that never got renewed.
Clinical buyers aren't cynical by nature. They're cynical by experience. Health tech marketing has trained them to treat every unlabeled claim as decoration, because for years, most of it was.
That training works against you the moment you publish something premature, and it works for you the moment you publish something specific. A logo with no detail behind it reads as decoration. A logo with a named contact, a defined metric and an honest account of where things stand reads as something else entirely: a company that understands what proof actually requires.
Investors read the same signal differently but land in the same place. They've sat through a hundred pitches with a slide that says "backed by leading health systems" and means one unsigned letter of intent. When they see a claim dressed up to look bigger than it is, they don't just discount the claim. They start discounting your judgment.
The logo is just premature, and premature proof reads as weaker than no proof at all. It signals you don't yet know the difference between the two.
The four things that turn a logo into proof
I don't think this needs to be complicated. A pilot logo becomes real proof once four things are true.
A defined outcome existed before the pilot started. Not "let's see how it goes." A specific metric, agreed in writing, that both sides knew they were measuring from day one. If you can't point to the sentence where you agreed what success looked like, you don't have an outcome yet. You have a hope, and hopes don't hold up under a clinician's second question.
There's a baseline to compare against. "Patients booked 40% more follow-ups" means nothing without knowing what the follow-up rate was before you showed up. Most pilots skip this because baselining feels like admin, not progress, and nobody wants to spend week one measuring instead of building. It's the single habit that pays off most later, and almost nobody does it early enough.
Someone specific is willing to say something specific. Not a marketing-approved quote about how easy the integration was. A named person willing to describe what changed, in their own words, that they'd stand behind if a colleague asked them about it directly, in a hallway, with no marketing team listening. If your pilot contact won't do that yet, the pilot isn't done, whatever the calendar says.
You'd be uncomfortable if the result reversed. This is the test I trust most. If you'd be fine publishing the opposite of what you're claiming, because the claim is vague enough to survive either outcome, it was never a real claim. Real proof has a wrong answer built into it. "Patients loved it" survives any outcome. "No-show rate dropped from 22% to 14% over eight weeks" does not, and that's exactly why it's worth more.
Until all four are true, what you have is a relationship, not proof. That's worth having. It's just a different thing, and it deserves different language.
What to publish while you wait
Here's the part founders get wrong most often: they think the choice is between publishing the logo early or publishing nothing at all.
There's a third option, and it's usually better than either. Publish the thinking, not the result.
Write about how you're running the pilot. What you're measuring and why you picked that metric over the obvious one. What you expected going in, what's already surprised you three weeks in, even though the final number isn't there yet. What almost went sideways in week two and what you changed because of it.
Say you're building a scheduling tool for multi-site physiotherapy groups. Instead of a logo and a vague claim about efficiency, you could publish 800 words on why you chose cancellation rate over utilization as your primary pilot metric, and what that choice tells a clinic director about how you think. That piece does something a finished case study can't do yet: it proves you know what a rigorous test looks like, before you have the result to show for it.
A clinician evaluating your product doesn't only want to know it worked somewhere else. She wants to know you understand her world well enough to test the right thing in the first place. Methodology is its own credibility signal. You're allowed to publish it before the outcome exists, and honestly, you should.
I've watched this content type do more for trust than a premature logo ever does, because nobody can dismiss it as spin. It's hard to accuse a founder of exaggerating when the post is just an honest account of how a metric got chosen.
Confidence without inflation
None of this means undercutting the pilot itself. You can be genuinely excited about a design partner relationship and precise about what it's proven so far. Those sit fine together.
Say it plainly on your homepage: "We're running an active pilot with a multi-site physiotherapy group, testing whether same-day scheduling changes no-show rate, with results expected in Q2." That's confident. It's also accurate. A clinician reading it doesn't need you to promise an outcome you don't have. She needs to know you're testing something real, with someone real, and that you'll say what you find either way, good or bad.
The founders who get this wrong usually aren't lying. They're uncomfortable with uncertainty, so they round it up to something that sounds finished before it is. Being exact about where you actually stand is its own form of confidence, and clinical buyers recognize it as the real kind almost immediately.
The fundraising version of the same mistake
If you're prepping for a raise, this pattern shows up again in your deck, wearing a different outfit.
An investor who's evaluated a dozen digital health companies this quarter has seen the "pilot with [redacted health system]" slide a dozen times. It tells them almost nothing, because it was written to sound bigger than it is. What actually moves the needle is the same four-part structure from above: defined outcome, baseline, named voice, a claim with a wrong answer built in.
If you don't have that yet, say what you're measuring and when you'll know it. "We'll have a completed 90-day cohort with baseline data by March" is a more credible sentence than a logo with a quiet asterisk next to it, because it shows you already understand what proof requires. Investors aren't only underwriting your product. They're underwriting your judgment about what counts as evidence. Show them you have that judgment before you have the result that would prove it worked anyway.
The cost of getting the sequencing wrong
None of this is an argument for waiting until you have a polished case study before you publish anything. Waiting is its own mistake, and it's the one I see costing founders more than premature logos do.
Every month you don't publish anything is a month a buyer forms an opinion about your category with you nowhere in the room. Silence doesn't protect your credibility. It just means someone else's content fills the gap, usually a competitor with less to say but more of it already published.
Silence has a cost too, and a bare logo has a different one. Sequencing is what avoids both.
Sequencing
Publish the relationship as a relationship first: a pilot underway, a partnership announced, a specific problem you're working on together, without dressing it up as an outcome it hasn't produced yet. Then publish the outcome, with the specificity it deserves, once you've earned the right to that specificity.
A pilot logo with no story behind it invites the exact scrutiny you're not ready for yet. A pilot described honestly, with a clear methodology and an open question about what you'll find, invites something better. A buyer reads it and thinks: these people know what they're doing before they even know what they'll find.
That's proof of a different kind. And it's the kind you're allowed to have on day one.